ClinicalTrials.gg
CompletedNCT02561988Updated Mar 17, 2023

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

A Phase 1 interventional study of Avapritinib in Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease and Mast Cell Leukemia, sponsored by Blueprint Medicines Corporation. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-17.

Primary conditionLeukemia, Mast-CellRegistry: Mastocytosis, SystemicReclassifiedWhy we changed it
Registry
Mastocytosis, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Mast-Cell
Why
  1. The study's listed conditions name Leukemia, Mast-Cell, a narrower term within Mastocytosis, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Leukemia, Mast-Cell with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Mast-Cell · United States.

Enrollment
13th of 34
86 · median 45
Started
2016
the only one that year
Phase 1
6 of 48
none open now
Registered
38th of 48
by date
Lead sponsor
5 of 48
Blueprint Medicines Corporation

Among the 48 studies in Leukemia, Mast-Cell with a site in United States, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2016, is one of 6 in phase 1, and was the 38th registered.

Leukemia, Mast-Cell

60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.

Browse Leukemia, Mast-Cell studies →

Open to participants now

4 of the 48 studies in Leukemia, Mast-Cell with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Leukemia, Mast-Cell studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Leukemia, Mast-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

03

Conditions studied

  • Aggressive Systemic Mastocytosis
  • Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
  • Mast Cell Leukemia
  • Relapsed or Refractory Myeloid Malignancies

Browse trials for

04

In context

Leukemia, Mast-Cell Reclassified

60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.

This study's enrollment of 86 is above the median of 50 across 38 interventional studies indexed under Leukemia, Mast-Cell.

Browse Leukemia, Mast-Cell studies →

Lead sponsor

Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.

First submitted before Blueprint Medicines Corporation became part of Sanofi.

Compared within Leukemia, Mast-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mastocytosis, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part 1:Patients must have one of the following diagnoses based on World Heath Organization (WHO) diagnostic criteria:

  • Aggressive systemic mastocytosis (ASM).
  • Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and at least 1 C-finding attributable to systemic mastocytosis (SM). The AHN must be myeloid, with the following exceptions that are excluded: Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS) that is very high- or high-risk as defined by the International prognostic scoring system for myelodysplastic syndromes (IPSS-R) and Philadelphia chromosome positive .
  • Mast cell leukemia (MCL).
  • - or cytologically- confirmed myeloid malignancy that is to standard treatments. AML, MDS that is very high- or high-risk as defined by the IPSS-R, and Philadelphia chromosome positive malignancies are excluded.
  • Upon discussion with the sponsor, other relapsed or refractory, potentially avapritinib-responsive hematologic neoplasms (e.g., evidence of aberrant KIT or derived growth factor receptor (PDGFR) signaling) may be considered for enrollment.

For Part 2, patients must have one of the following diagnoses, based on WHO diagnostic criteria:

  • ASM.
  • SM-AHN. The AHN must be myeloid, with the following exceptions that are excluded: AML, MDS that is very high- or high-risk as defined by the IPSS-R, and Philadelphia chromosome positive malignancies.
  • MCL.

For Part 2, Cohort 2, patients must have at least 1 measurable C-finding per modified IWG-MRT-ECNM criteria at Baseline, attributed to SM unless diagnosis is MCL, which does not require a C-finding.

  • Cytopenias: ANC \< 1.0 × 10⁹/L or \< 10 g/dL or platelet count \< 75 × 10⁹/L.
  • Symptomatic ascites or pleural effusion requiring medical intervention such as: use of diuretics (Grade 2) or ≥ 2 therapeutic paracenteses or thoracenteses (Grade 3) at least 28 days apart over the 12 weeks before study entry and 1 of the procedures is performed during the 6 weeks before study start (C1D1).
  • ≥ Grade 2 abnormalities in direct (> 1.5 × [ULN]), (AST; > 3.0 × ULN), alanine aminotransferase (ALT; > 3.0 × ULN), or alkaline phosphatase (> 2.5 × ULN) with 1 of the following present: ascites or portal hypertension or liver mast cell infiltration that is -proven or no other identified cause of abnormal liver function.
  • ≥ Grade 2 hypoalbuminemia (\< 3.0 g/dL).
  • A spleen that is palpable ≥ 5 cm below the left costal margin.
  • Transfusion-dependent anemia defined as: transfusion of ≥ 6 units packed red blood cells (PRBCs) in the 12 weeks before start of treatment (C1D1) and most recent transfusion occurring during the preceding 4 weeks and transfusion administered for hemoglobin ≤ 8.5 g/dL and reason for transfusion is not bleeding, hemolysis, or therapy-related.

(ECOG) performance status of 0-3.

Exclusion criteria

Exclusion Criteria:

  • corrected using Fridericia's formula (QTcF) >480 milliseconds
  • count \<50,000/μL (within 4 weeks of the first dose of study drug) or receiving platelet transfusion(s)
  • \<500/μL
  • (AST) and alanine aminotransferase (ALT) >3 x the (ULN); >5 × ULN if associated with clinically suspected liver infiltration by mastocytosis or another disease for which the patient enrolled into the study
  • Total >1.5 × ULN; >3 × ULN if associated with liver infiltration by the disease being treated or in the presence of Gilbert's Disease (In the case of Gilbert's disease, a direct bilirubin > 2.0 ULN would be an exclusion.)
  • Estimated (Cockroft-Gault formula) or measured \<40 mL/min
  • Brain or to the brain
  • History of a seizure disorder or requirement for anti-seizure medication
  • Known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding
  • Eosinophilia and known positivity for the FIP1L1-PGDFRA fusion, unless the patient has demonstrated relapse or progressive disease on prior imatinib therapy
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Avapritinib (also known as BLU-285)

    Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.

    Drug: Avapritinib

Interventions

07

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of avapritinib (also known as BLU-285)

    Time frame: During cycle 1 (28 days) of treatment

  2. Number of patients with adverse and serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings

    Time frame: Approximately 24 months

  3. Recommended Phase 2 dose (RP2D) of avapritinib

    Time frame: Approximately 24 months

Secondary outcomes

  1. Maximum plasma concentration of avapritinib

    Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 8 and 24 hrs post dose (plus 10 and 48 hrs post dose in Part 2) on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1

    Time frame: Every cycle (28 days) up to cycle 4

  2. Time to maximum plasma concentration of avapritinib

    Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 8 and 24 hrs post dose (plus 10 and 48 hrs post dose in Part 2) on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1

    Time frame: Every cycle (28 days) up to cycle 4

  3. Overall Response Rate

    Including complete remission (CR), CR with partial recovery of peripheral blood (CRh), partial remission (PR) and clinical improvement (CI) using modified International Working Group Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European competence network on mastocytosis (ECNM) criteria; and duration of response (DOR)

    Time frame: 8, 24, 40, 68 and every 24 weeks until patient terminates from the study (approximately 24 months)

  4. Morphologic response

    Including morphologic complete remission (mCR), morphologic CR with partial recovery of peripheral blood (mCRh), and morphologic partial remission (mPR) based on Pure Pathologic Response

    Time frame: ≥ 12 weeks

  5. Changes in levels of serum tryptase and levels of V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) D816V allele burden in blood

    Time frame: Cycle (C)1Day (D)1, C1D15, C2D1, C3D1, C5D1, C7D1, C11D1, C18D1 every 6 cycles thereafter and at disease progression. (approximately 24 months)

  6. Changes in patient reported symptoms and quality of life using the Patient Global Impression of Symptom Severity (PGIS) scale

    Defined as change from Baseline

    Time frame: Part 2 only - Day 1 of Cycles 1-12

  7. Changes in patient reported quality of life using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C-30)

    Defined as change from Baseline

    Time frame: Part 2 only - Day 1 of Cycles 1-12

  8. Changes in patient reported outcomes using the advanced SM symptom assessment form (AdvSM-SAF)

    Defined as change from Baseline

    Time frame: Part 2 only - daily from Day -7 through Cycle 12

  9. Change in liver volume by imaging

    mL

    Time frame: Day 1 of Cycles 5-18, and every 6 cycles thereafter (each cycle is 28 days)

  10. Change in spleen volume by imaging

    mL

    Time frame: Day 1 of Cycles 5-18, and every 6 cycles thereafter (each cycle is 28 days)

08

Study locations

11 sites
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • University of Colorado Cancer Center
    Denver, Colorado 80045, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0XL, United Kingdom
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Reiter A, Gotlib J, Alvarez-Twose I, Radia DH, Lubke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022 Aug;36(8):2108-2120. doi: 10.1038/s41375-022-01615-z. Epub 2022 Jul 5. PubMed 35790816 ↗
  • Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, Alvarez-Twose I, Vannucchi AM, Panse J, Platzbecker U, Hermine O, Dybedal I, Lin HM, Rylova SN, Ehlert K, Dimitrijevic S, Radia DH. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022 Nov 8;6(21):5750-5762. doi: 10.1182/bloodadvances.2022007539. PubMed 35640224 ↗
  • DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6. PubMed 34873347 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Oct 2022, 78 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2015
First posted
Sep 29, 2015
StartActual
Mar 10, 2016
Primary completionActual
Oct 5, 2022
CompletionActual
Jan 19, 2023
Last update
Mar 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02561988
Responsible party
Sponsor
First posted
Sep 29, 2015
Start date
Mar 10, 2016
Primary completion
Oct 5, 2022
Completion
Jan 19, 2023
Last update
Mar 17, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion